Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Microdose therapy










Image Number 2 for United States Patent #6610652.

Methods for treating vascular conditions associated with localized imbalance in vascular tone, which are hypothesized to be largely due to elevated endothelin (ET) are provided. The methods involve administration of nitric oxide (NO), agents which are able to provide NO, such as NO donors, agents which activate guanyl cyclase, such as YC-1, or agents which prolong the actions of endogenous NO or cyclic guanosine monophosphate (cGMP; a 2nd messenger molecule), such as phosphodiesterase (PDE) inhibitors. According to the invention, such agents are administered in minimal doses or microdoses by any route known in the art, so as to provide dosages which are about one half to about one twentieth (1/2 to 1/20) of those known to induce vasodilation in "normal" circulations. The low doses of these agents effectively alleviate vascular conditions associated with a reduction in NO production or an attenuation of NO effect, by restoring balance in vascular tone while exerting almost no systemic effect in normal vasculature.








 
 
  Recently Added Patents
Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
Highly detectable pilot structure
Mesa-shaped piezoelectric resonator element
Bend resistant cable
Pipette device
Image forming apparatus
Circuit arrangement for a piezo transformer, and method therefor
  Randomly Featured Patents
Method utilizing camshaft miller
Contrast agent for photoacoustic imaging and photoacoustic imaging method
Card holder for window display
Flexible tube having a variable stiffness bellows
Method and apparatus for improving channel estimation
Friction pad mounting means for a disc brake caliper
Process for the production of 3-alky-3-hydroxymethyloxetanes
Optical drop circuit having group delay compensation
Shotshell cartridge adapter
Tetrasubstituted imidazole derivatives as cannabinoid CB.sub.1 receptor modulators with a high CB.sub.1/CB.sub.2 receptor subtype selectivity